Skip to content
Assyro AI
FDA Orange Book · active-ingredient family

Flutamide

Flutamide: 1 brand, 5 generics; first approved Jan 27, 1989; generic available.

Generic availableHas discontinued products
Generic status & protection

Generic available: 5 ANDA applications approved.

Brands (NDA)
1
Generics (ANDA)
5
Listed patents
0
Presentations
6

Brand (NDA) products

Originator applications
  • NDA 0185541989
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    125MGCAPSULEORALDiscontinued—

Generic (ANDA) products (5)

Abbreviated applications
  • FLUTAMIDE
    ANDA 0762242003
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    125MGCAPSULEORALDiscontinued—
  • FLUTAMIDE
    ANDA 0757802001
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    125MGCAPSULEORALDiscontinued—
  • FLUTAMIDE
    ANDA 0758202001
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    125MGCAPSULEORALDiscontinued—
  • FLUTAMIDE
    ANDA 0758182001
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    125MGCAPSULEORALDiscontinued—
  • FLUTAMIDERS
    ANDA 0752982001
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    125MGCAPSULEORALRx—

Listed patents

Orange Book patent file

No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Approval history

FDA approval span
First approval
38 yr 3 mo ago
Most recent approval
23 yr 9 mo ago

Approvals span 1989–2003 across 6 FDA applications.

Brand (NDA) 117%
Generic (ANDA) 583%

Flutamide: frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Built directly from the FDA Orange Book data file (products, patents, and exclusivity). TE codes, RLD/RS flags, patent expirations, and exclusivity dates match the official FDA record. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Related FDA reference tools

Go beyond the database.

Try Assyro Intelligence for your regulatory research. Ready to discuss your team’s workflow? Book a demo.